Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 29, 2011

FDA Clears Centocor’s Zytiga as Combination Therapy for Metastatic Prostate Cancer

  • FDA has rubber-stamped Centocor Ortho Biotech’s Zytiga™ (abiraterone acetate) as combination therapy with prednisone for the treatment of metastatic castration-resistant prostate cancer in men who have received prior docetaxel-based chemotherapy.

    Approval in the U.S. was based on data from a 1,195-patient Phase III trial (COU-AA-301), which demonstrated that the combination of oral, once-daily Zytiga and prednisone led to a 35% reduction in the risk of death and a 3.9 month improvement in median survival compared with prednisone therapy alone.

    Zytiga is an oral androgen biosynthesis inhibitor designed to block the CYP17 enzyme complex required for production of androgen in the testes, adrenal glands, and in the prostate in prostate cancer patients. The FDA application, submitted in December, was given priority review status. Also in December partner Janssen-Cilag filed a marketing authorization application for abiraterone acetate with the European Medicines Agency. Under terms of the firms’ deal for Zytiga, abiraterone acetate will be commercialized and distributed by Centocor Ortho Biotech in the U.S. and, pending relevant approvals, by Janssen Pharmaceutical companies in all other global markets.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.